Skip to main content

Events

There are no upcoming events at this time.

News

  • Besheer researching Ozempic’s potential to treat alcohol, opioid addiction

    BCAS Associate Director Dr. Joyce Besheer is researching the potential of Ozempic, a popular diabetes and weight loss medication, to treat alcohol and opioid addiction. Her work was cited in the news media: Ozempic may lead to decrease in drinking

  • Dr. Zoe McElligott and ‘Avengers’ research team make xylazine discovery

    Congratulations to the “Avengers” Research Team, led by BCAS faculty member Dr. Zoe McElligott! As part of the Triangle Center of Excellence in Regulatory Science and Innovation (Triangle CERSI), this team has made significant progress in addressing a pressing public health issue. Awarded an FDA grant, the team is studying the effects of xylazine, a … Read more

  • Coleman wins ASPET Early Career Award

    BCAS faculty member Leon Coleman, MD, PhD has received the 2025  Division for Neuropharmacology Early Career Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET) . The ASPET Division for Neuropharmacology established this award to recognize and honor a young independent investigator working in neuropharmacology. The award recognizes Dr. Coleman’s his publication quality, research originality, teaching … Read more

  • Fulton Crews quoted on Good Morning America

    Fulton Crews, professor of pharmacology and psychiatry at the UNC School of Medicine, was quoted in an ABC Good Morning America article discussing drinking habits and the benefits of Dry January. The article was originally published in 2018 and was republished this month: Dry January: What is it and how beneficial can giving up alcohol … Read more

  • Lopez discovers new mechanism for allopregnanolone inhibition of inflammatory signaling

    Alejandro Lopez, a graduate research assistant at the Bowles Center for Alcohol Studies, has just discovered a new mechanism for allopregnanolone inhibition of inflammatory signaling. Allopregnanolone inhibits binding of lipopolysaccaride (LPS) to it’s binding site in the binding pocket of the toll-like receptor: Myeloid differentiation factor-2 (TLR4:MD2) protein complex with nanomolar affinity.  Such high affinity … Read more

 

 

More News…